Published in PLoS One on July 10, 2017
Unravelling the pathogenesis of inflammatory bowel disease. Nature (2007) 18.52
A microbial symbiosis factor prevents intestinal inflammatory disease. Nature (2008) 13.15
Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol (2005) 11.18
Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol (2006) 7.75
Activation of the IkappaB alpha kinase complex by MEKK1, a kinase of the JNK pathway. Cell (1997) 3.91
Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature (1999) 3.59
Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity (2002) 3.46
Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest (2001) 2.73
Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2012) 2.46
Cytokines, inflammation, and pain. Int Anesthesiol Clin (2007) 2.01
Regulation of TGF-beta signaling by Smad7. Acta Biochim Biophys Sin (Shanghai) (2009) 1.87
Role of "Western diet" in inflammatory autoimmune diseases. Curr Allergy Asthma Rep (2014) 1.79
Evolution in health and medicine Sackler colloquium: Evolution of the human lifespan and diseases of aging: roles of infection, inflammation, and nutrition. Proc Natl Acad Sci U S A (2009) 1.79
Smad3: a key player in pathogenetic mechanisms dependent on TGF-beta. Ann N Y Acad Sci (2003) 1.74
Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol (2000) 1.54
Intestinal permeability--a new target for disease prevention and therapy. BMC Gastroenterol (2014) 1.52
TGF beta signalling and its role in tumour pathogenesis. Acta Biochim Pol (2005) 1.36
Essential role for Smad3 in regulating MCP-1 expression and vascular inflammation. Circ Res (2004) 1.26
T-cell activation in the intestinal mucosa. Immunol Rev (2007) 1.20
Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease. Pathol Int (2002) 1.12
Ulcerative colitis. BMJ (2000) 1.11
Distinct effects of TGF-beta 1 on CD4+ and CD8+ T cell survival, division, and IL-2 production: a role for T cell intrinsic Smad3. J Immunol (2005) 1.05
Human serum IgA downregulates the release of inflammatory cytokines (tumor necrosis factor-alpha, interleukin-6) in human monocytes. Blood (1994) 1.05
The B-cell system in inflammatory bowel disease. Adv Exp Med Biol (2006) 1.04
p53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma. Hum Pathol (1994) 0.99
Cooperativity among secretory IgA, the polymeric immunoglobulin receptor, and the gut microbiota promotes host-microbial mutualism. Immunol Lett (2014) 0.97
Intravital observation of adhesion of lamina propria lymphocytes to microvessels of small intestine in mice. Gastroenterology (2002) 0.93
Bovine glycomacropeptide ameliorates experimental rat ileitis by mechanisms involving downregulation of interleukin 17. Br J Pharmacol (2008) 0.91
Classical and recent advances in the treatment of inflammatory bowel diseases. Braz J Med Biol Res (2014) 0.88
The implications of oxidative stress and antioxidant therapies in Inflammatory Bowel Disease: Clinical aspects and animal models. Saudi J Gastroenterol (2016) 0.88
Bovine glycomacropeptide is anti-inflammatory in rats with hapten-induced colitis. J Nutr (2005) 0.88
Antioxidant therapy for treatment of inflammatory bowel disease: Does it work? Redox Biol (2015) 0.87
CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity. Clin Chim Acta (2013) 0.86
The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies. Blood Cancer J (2015) 0.86
Diet, gut microbes, and the pathogenesis of inflammatory bowel diseases. Mol Nutr Food Res (2016) 0.85
The effect of bifid triple viable on immune function of patients with ulcerative colitis. Gastroenterol Res Pract (2012) 0.82
Bovine glycomacropeptide induces cytokine production in human monocytes through the stimulation of the MAPK and the NF-kappaB signal transduction pathways. Br J Pharmacol (2009) 0.82
Oxazolone-induced colitis in rats: effects of budesonide, cyclosporin A, and 5-aminosalicylic acid. Scand J Gastroenterol (1998) 0.82
Immunoregulatory Role of Myeloid-derived Cells in Inflammatory Bowel Disease. Inflamm Bowel Dis (2015) 0.81
Validation of bovine glycomacropeptide as an intestinal anti-inflammatory nutraceutical in the lymphocyte-transfer model of colitis. Br J Nutr (2013) 0.81
Basic and clinical research on the regulation of the intestinal barrier by Lactobacillus and its active protein components: a review with experience of one center. Mol Biol Rep (2014) 0.80
Recent progress on the role of gut microbiota in the pathogenesis of inflammatory bowel disease. J Dig Dis (2013) 0.79
TGFbeta1 expression in colonic mucosa: modulation by dietary lipids. Genes Nutr (2007) 0.77
[Expression of co-stimulators in ulcerative colitis and its pathologic significance]. Zhonghua Bing Li Xue Za Zhi (2010) 0.77
Increased migration of IgA lymphocytes to VIP nerve fibers after DSS-induced colitis. Histol Histopathol (2011) 0.76
Immunotherapy of inflammatory bowel diseases: current concepts and future perspectives. Arch Immunol Ther Exp (Warsz) (2000) 0.76
Endoscopic finding of spontaneous hemorrhage correlates with tumor necrosis factor alpha expression in colonic mucosa of patients with ulcerative colitis. Int J Colorectal Dis (2013) 0.76
Casein glycomacropeptide for active distal ulcerative colitis: a randomized pilot study. Eur J Clin Invest (2016) 0.76
IBD: In Food We Trust. J Crohns Colitis (2016) 0.76